TY - JOUR
T1 - The pharmaco-epigenetics of hypertension
T2 - a focus on microRNA
AU - Yaacoub, Serge
AU - Boudaka, Ammar
AU - AlKhatib, Ali
AU - Pintus, Gianfranco
AU - Sahebkar, Amirhossein
AU - Kobeissy, Firas
AU - Eid, Ali H.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/2/29
Y1 - 2024/2/29
N2 - Hypertension is a major harbinger of cardiovascular morbidity and mortality. It predisposes to higher rates of myocardial infarction, chronic kidney failure, stroke, and heart failure than most other risk factors. By 2025, the prevalence of hypertension is projected to reach 1.5 billion people. The pathophysiology of this disease is multifaceted, as it involves nitric oxide and endothelin dysregulation, reactive oxygen species, vascular smooth muscle proliferation, and vessel wall calcification, among others. With the advent of new biomolecular techniques, various studies have elucidated a gaping hole in the etiology and mechanisms of hypertension. Indeed, epigenetics, DNA methylation, histone modification, and microRNA-mediated translational silencing appear to play crucial roles in altering the molecular phenotype into a hypertensive profile. Here, we critically review the experimentally determined associations between microRNA (miRNA) molecules and hypertension pharmacotherapy. Particular attention is given to the epigenetic mechanisms underlying the physiological responses to antihypertensive drugs like candesartan, and other relevant drugs like clopidogrel, aspirin, and statins among others. Furthermore, how miRNA affects the pharmaco-epigenetics of hypertension is especially highlighted.
AB - Hypertension is a major harbinger of cardiovascular morbidity and mortality. It predisposes to higher rates of myocardial infarction, chronic kidney failure, stroke, and heart failure than most other risk factors. By 2025, the prevalence of hypertension is projected to reach 1.5 billion people. The pathophysiology of this disease is multifaceted, as it involves nitric oxide and endothelin dysregulation, reactive oxygen species, vascular smooth muscle proliferation, and vessel wall calcification, among others. With the advent of new biomolecular techniques, various studies have elucidated a gaping hole in the etiology and mechanisms of hypertension. Indeed, epigenetics, DNA methylation, histone modification, and microRNA-mediated translational silencing appear to play crucial roles in altering the molecular phenotype into a hypertensive profile. Here, we critically review the experimentally determined associations between microRNA (miRNA) molecules and hypertension pharmacotherapy. Particular attention is given to the epigenetic mechanisms underlying the physiological responses to antihypertensive drugs like candesartan, and other relevant drugs like clopidogrel, aspirin, and statins among others. Furthermore, how miRNA affects the pharmaco-epigenetics of hypertension is especially highlighted.
KW - Antihypertensive response
KW - Aspirin
KW - Blood pressure
KW - Cardiovascular disease
KW - Clopidogrel
KW - Endothelium
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=85186629997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85186629997&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/b8995900-242b-34c9-b8a9-b974cb28e3b8/
U2 - 10.1007/s11010-024-04947-9
DO - 10.1007/s11010-024-04947-9
M3 - Review article
C2 - 38424404
AN - SCOPUS:85186629997
SN - 0300-8177
JO - Molecular and Cellular Biochemistry
JF - Molecular and Cellular Biochemistry
ER -